Fractyl Laboratories

First patients enrolled in multicenter trial of Fractyl Revita DMR System

Friday, July 17, 2015

Fractyl Laboratories, a private company based in Waltham, Mass., has begun patient enrollment in a multicenter clinical trial (Revita-1) being conducted in Europe and South America to evaluate the safety and performance of the Revita Duodenal Mucosal Resurfacing (DMR) System. Revita is the first non-invasive, implant free duodenal resurfacing procedural therapy designed to directly treat the digestive causes of insulin resistance in patients with uncontrolled type 2 diabetes.

[Read More]